Mylan Loses Bid to Dismiss Lawsuit A U.S. district judge has ruled that a class action lawsuit against Mylan Inc.,… Read more »
Tag: DBV technologies
DBV Cuts Costs Awaiting FDA; Unveils More Peanut Patch Results
With much of the Food and Drug Administration’s staff working on the coronavirus pandemic, the timeline for reviews of some… Read more »
Study Shows High Costs and Burden of Peanut Allergy
A study of a large U.S. health insurer database reveals the high dollar and health costs for those living with… Read more »
3 in 4 Kids See Benefit From Viaskin Peanut Patch After 3 Years
After three years of using the Viaskin Peanut patch in children ages 4 to 11, more than half (52 percent)… Read more »
Viaskin Peanut Patch Submitted to FDA for Approval Consideration
The manufacturer of the Viaskin Peanut patch has resubmitted its biologics license application (or BLA) to the FDA – in… Read more »
Peanut Allergy Therapies: ICER’s Review Draws Criticism
What do you get when you undertake a cost-benefit analysis of new therapies when prices have yet to be established… Read more »
Viaskin Peanut Patch Back on the FDA Approval Track for Fall 2019
The manufacturer of the Viaskin Peanut patch has announced plans to resubmit its biologics license application (BLA) for the therapy… Read more »
Patch Progress, Peanut OIT in Adults Data Presented at EAACI Meeting
We’re learning more about the two therapies to treat peanut allergies that could soon be available in allergist’s offices in… Read more »
DBV Plans to Move Forward with Milk Allergy Patch for Younger Kids
French pharmaceutical maker DBV Technologies says researchers in a Phase 2 trial of the Viaskin Milk patch observed “statistically significant… Read more »
Peanut Patch Shows Progress in Kids in One-Year Findings
Almost half of youngsters could consume 10 times more peanut than at start of study.